Menu
Jennifer, has over two decades of commercial leadership experience in the biotech and pharmaceutical industries. With a proven track record in orchestrating successful launches in high-growth environments, she has adeptly guided both established enterprises and startups through complex market landscapes, aligning commercial strategies with evolving healthcare paradigms.
As Vice President of Marketing at Impel Pharmaceuticals, Jennifer led the end-to-end commercial strategy for Trudhesa® in the competitive migraine market. At Novartis Pharmaceuticals, she orchestrated the global launch of Aimovig®, achieving substantial market share within the preventive calcitonin gene-related peptide (CGRP) segment across thirty-one markets. Jennifer‘s expertise in migraine extends to her tenure at electroCore, where she formulated a comprehensive commercialization strategy for a neuromodulation therapy, surpassing launch goals and securing reimbursement in key markets.
At Brightmind.AI, Jennifer will help prepare a successful G2M in key markets across the globe.